| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 11 | 2023 | 60 | 3.340 |
Why?
|
| Hepatitis, Alcoholic | 14 | 2025 | 77 | 2.410 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2021 | 620 | 2.220 |
Why?
|
| Edible Grain | 8 | 2011 | 27 | 1.790 |
Why?
|
| Cat Diseases | 3 | 2022 | 17 | 1.760 |
Why?
|
| Female | 171 | 2025 | 32611 | 1.580 |
Why?
|
| Aspirin | 6 | 2025 | 171 | 1.380 |
Why?
|
| Dogs | 13 | 2023 | 325 | 1.350 |
Why?
|
| Child | 84 | 2023 | 4484 | 1.350 |
Why?
|
| Thromboxane B2 | 4 | 2025 | 17 | 1.330 |
Why?
|
| Male | 115 | 2025 | 29603 | 1.290 |
Why?
|
| Dietary Fats | 11 | 2011 | 176 | 1.260 |
Why?
|
| Humans | 208 | 2025 | 62953 | 1.210 |
Why?
|
| Adolescent | 69 | 2021 | 6202 | 1.190 |
Why?
|
| Cholesterol, LDL | 18 | 2018 | 103 | 1.170 |
Why?
|
| Obesity | 24 | 2015 | 1232 | 1.160 |
Why?
|
| Child Nutritional Physiological Phenomena | 8 | 2009 | 26 | 1.120 |
Why?
|
| Puberty | 14 | 2020 | 59 | 1.070 |
Why?
|
| Body Mass Index | 33 | 2017 | 864 | 1.020 |
Why?
|
| Retrospective Studies | 27 | 2025 | 6564 | 1.010 |
Why?
|
| Adrenalectomy | 2 | 2016 | 25 | 0.980 |
Why?
|
| Echocardiography | 4 | 2020 | 500 | 0.970 |
Why?
|
| Feeding Behavior | 11 | 2011 | 259 | 0.950 |
Why?
|
| Enteritis | 1 | 2025 | 14 | 0.940 |
Why?
|
| Ulcer | 1 | 2025 | 14 | 0.940 |
Why?
|
| Thromboxanes | 2 | 2024 | 9 | 0.940 |
Why?
|
| Adult | 73 | 2025 | 16689 | 0.930 |
Why?
|
| End Stage Liver Disease | 5 | 2023 | 33 | 0.920 |
Why?
|
| Intestinal Obstruction | 1 | 2025 | 53 | 0.910 |
Why?
|
| Analgesics, Opioid | 12 | 2023 | 532 | 0.910 |
Why?
|
| Intestine, Small | 1 | 2025 | 79 | 0.900 |
Why?
|
| Lipids | 6 | 2020 | 316 | 0.850 |
Why?
|
| Crohn Disease | 1 | 2025 | 111 | 0.840 |
Why?
|
| Neurofibromatosis 1 | 2 | 2021 | 32 | 0.840 |
Why?
|
| Longitudinal Studies | 34 | 2021 | 1253 | 0.820 |
Why?
|
| Body Composition | 8 | 2017 | 152 | 0.820 |
Why?
|
| Research Design | 12 | 2019 | 573 | 0.800 |
Why?
|
| Diet | 13 | 2020 | 523 | 0.790 |
Why?
|
| Biomarkers | 14 | 2025 | 1388 | 0.760 |
Why?
|
| Morphine | 10 | 2023 | 59 | 0.760 |
Why?
|
| Hyperglycemia | 2 | 2020 | 104 | 0.750 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 2 | 2018 | 13 | 0.740 |
Why?
|
| Quarantine | 1 | 2021 | 11 | 0.740 |
Why?
|
| Diet, Fat-Restricted | 5 | 2010 | 33 | 0.710 |
Why?
|
| Dyslipidemias | 1 | 2020 | 37 | 0.690 |
Why?
|
| Suicidal Ideation | 2 | 2018 | 116 | 0.680 |
Why?
|
| Heart Failure | 5 | 2025 | 904 | 0.670 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 63 | 0.670 |
Why?
|
| Surveys and Questionnaires | 12 | 2021 | 2655 | 0.660 |
Why?
|
| Quality of Life | 5 | 2021 | 1222 | 0.660 |
Why?
|
| Bed Rest | 1 | 2019 | 11 | 0.660 |
Why?
|
| Age Factors | 21 | 2023 | 1558 | 0.650 |
Why?
|
| Body Weight | 10 | 2014 | 377 | 0.650 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2019 | 3 | 0.640 |
Why?
|
| Peristalsis | 1 | 2019 | 5 | 0.640 |
Why?
|
| Animals | 40 | 2023 | 20630 | 0.640 |
Why?
|
| Cephalosporins | 1 | 2019 | 18 | 0.640 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2019 | 50 | 0.620 |
Why?
|
| Middle Aged | 44 | 2025 | 17423 | 0.620 |
Why?
|
| Chickens | 1 | 2019 | 94 | 0.620 |
Why?
|
| Gastrointestinal Tract | 2 | 2019 | 181 | 0.610 |
Why?
|
| Behavior Therapy | 4 | 2024 | 165 | 0.610 |
Why?
|
| Risk Assessment | 8 | 2025 | 2054 | 0.610 |
Why?
|
| Depression, Postpartum | 3 | 2016 | 132 | 0.610 |
Why?
|
| Risk Factors | 29 | 2025 | 5316 | 0.610 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2018 | 13 | 0.600 |
Why?
|
| Rabbits | 1 | 2019 | 332 | 0.600 |
Why?
|
| Cohort Studies | 25 | 2020 | 2553 | 0.600 |
Why?
|
| Aged | 40 | 2025 | 14297 | 0.590 |
Why?
|
| Ventricular Function, Right | 1 | 2018 | 28 | 0.590 |
Why?
|
| Case-Control Studies | 9 | 2025 | 1116 | 0.590 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 190 | 0.590 |
Why?
|
| Cardiovascular Diseases | 10 | 2024 | 832 | 0.590 |
Why?
|
| Radiology | 3 | 2021 | 248 | 0.580 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2016 | 43 | 0.580 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2018 | 44 | 0.580 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 95 | 0.570 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2022 | 65 | 0.560 |
Why?
|
| Dietary Fiber | 6 | 2011 | 75 | 0.560 |
Why?
|
| Energy Intake | 16 | 2020 | 171 | 0.550 |
Why?
|
| United States | 37 | 2024 | 7754 | 0.540 |
Why?
|
| Blood Glucose | 8 | 2021 | 485 | 0.540 |
Why?
|
| Cattle | 7 | 2020 | 309 | 0.520 |
Why?
|
| Hepatitis C, Chronic | 6 | 2013 | 88 | 0.520 |
Why?
|
| Mass Screening | 5 | 2021 | 687 | 0.510 |
Why?
|
| Veterinarians | 1 | 2015 | 4 | 0.500 |
Why?
|
| Opioid-Related Disorders | 4 | 2017 | 491 | 0.500 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 1593 | 0.490 |
Why?
|
| Opiate Substitution Treatment | 2 | 2015 | 204 | 0.490 |
Why?
|
| Prospective Studies | 24 | 2025 | 3266 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 2151 | 0.490 |
Why?
|
| Exercise | 11 | 2024 | 940 | 0.490 |
Why?
|
| Brain Ischemia | 1 | 2019 | 417 | 0.480 |
Why?
|
| Liver | 7 | 2024 | 846 | 0.480 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 588 | 0.470 |
Why?
|
| Cats | 4 | 2022 | 87 | 0.470 |
Why?
|
| Maternal Welfare | 1 | 2015 | 15 | 0.470 |
Why?
|
| Interferon-alpha | 7 | 2013 | 102 | 0.470 |
Why?
|
| Choline | 3 | 2020 | 21 | 0.470 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2015 | 20 | 0.470 |
Why?
|
| Ribavirin | 6 | 2013 | 23 | 0.470 |
Why?
|
| Buprenorphine | 2 | 2015 | 190 | 0.460 |
Why?
|
| Emergency Service, Hospital | 5 | 2020 | 1079 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 692 | 0.460 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 264 | 0.460 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2015 | 33 | 0.460 |
Why?
|
| Cross-Sectional Studies | 18 | 2023 | 2561 | 0.460 |
Why?
|
| Bone Density | 3 | 2015 | 134 | 0.460 |
Why?
|
| Management Audit | 1 | 2014 | 3 | 0.450 |
Why?
|
| Anticoagulants | 5 | 2020 | 495 | 0.440 |
Why?
|
| Peer Review, Health Care | 1 | 2014 | 17 | 0.440 |
Why?
|
| Vibration | 4 | 2017 | 26 | 0.440 |
Why?
|
| Medicaid | 2 | 2015 | 359 | 0.440 |
Why?
|
| Methadone | 1 | 2015 | 134 | 0.440 |
Why?
|
| Polyethylene Glycols | 7 | 2013 | 168 | 0.440 |
Why?
|
| Hypercholesterolemia | 5 | 2007 | 70 | 0.440 |
Why?
|
| Blood Pressure | 14 | 2011 | 515 | 0.440 |
Why?
|
| Risk Management | 1 | 2014 | 39 | 0.430 |
Why?
|
| Cognition | 6 | 2023 | 481 | 0.430 |
Why?
|
| Calcium, Dietary | 5 | 2007 | 29 | 0.420 |
Why?
|
| Health Care Costs | 1 | 2015 | 209 | 0.410 |
Why?
|
| Infection Control | 4 | 2019 | 106 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 787 | 0.410 |
Why?
|
| Hip Fractures | 3 | 2010 | 77 | 0.400 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 263 | 0.400 |
Why?
|
| Adiposity | 2 | 2012 | 83 | 0.400 |
Why?
|
| Vancomycin-Resistant Enterococci | 3 | 2018 | 12 | 0.400 |
Why?
|
| Antiviral Agents | 7 | 2013 | 322 | 0.400 |
Why?
|
| Cholesterol | 4 | 2010 | 259 | 0.390 |
Why?
|
| Milk | 4 | 2021 | 42 | 0.390 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 735 | 0.390 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 1644 | 0.390 |
Why?
|
| Parents | 5 | 2025 | 381 | 0.380 |
Why?
|
| Pain | 5 | 2021 | 407 | 0.370 |
Why?
|
| Treatment Outcome | 24 | 2024 | 5608 | 0.370 |
Why?
|
| Cross Infection | 3 | 2019 | 160 | 0.360 |
Why?
|
| Infant, Newborn | 17 | 2023 | 1349 | 0.360 |
Why?
|
| Prognosis | 9 | 2024 | 1734 | 0.360 |
Why?
|
| Dietary Proteins | 3 | 2003 | 42 | 0.360 |
Why?
|
| Accidental Falls | 3 | 2017 | 128 | 0.350 |
Why?
|
| Metformin | 3 | 2015 | 73 | 0.350 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 965 | 0.350 |
Why?
|
| Atrial Fibrillation | 4 | 2020 | 837 | 0.350 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 62 | 0.350 |
Why?
|
| Time Factors | 13 | 2024 | 3754 | 0.340 |
Why?
|
| Young Adult | 12 | 2021 | 4658 | 0.340 |
Why?
|
| Gonadal Hormones | 1 | 2010 | 5 | 0.340 |
Why?
|
| Pregnancy | 19 | 2023 | 2327 | 0.340 |
Why?
|
| Conscious Sedation | 3 | 2019 | 39 | 0.340 |
Why?
|
| Severity of Illness Index | 12 | 2023 | 1545 | 0.340 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 1195 | 0.330 |
Why?
|
| Child Nutrition Sciences | 1 | 2009 | 4 | 0.330 |
Why?
|
| Child, Preschool | 13 | 2021 | 1966 | 0.320 |
Why?
|
| Fatty Liver | 3 | 2021 | 108 | 0.320 |
Why?
|
| Quality Improvement | 1 | 2014 | 440 | 0.320 |
Why?
|
| Insulin | 5 | 2021 | 687 | 0.320 |
Why?
|
| Beverages | 2 | 2007 | 67 | 0.320 |
Why?
|
| Feeding and Eating Disorders | 5 | 2012 | 49 | 0.320 |
Why?
|
| Nutritional Status | 4 | 2008 | 98 | 0.320 |
Why?
|
| Clinical Competence | 4 | 2017 | 716 | 0.320 |
Why?
|
| Aging | 5 | 2017 | 744 | 0.320 |
Why?
|
| Atrial Remodeling | 2 | 2020 | 17 | 0.320 |
Why?
|
| Body Height | 8 | 2012 | 68 | 0.320 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 84 | 0.310 |
Why?
|
| Homes for the Aged | 2 | 2008 | 157 | 0.310 |
Why?
|
| Parity | 4 | 2017 | 72 | 0.310 |
Why?
|
| Patient Education as Topic | 4 | 2020 | 466 | 0.310 |
Why?
|
| Breast | 2 | 2010 | 183 | 0.310 |
Why?
|
| Patient Compliance | 3 | 2012 | 358 | 0.300 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 148 | 0.300 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 163 | 0.300 |
Why?
|
| Patient Portals | 2 | 2020 | 49 | 0.300 |
Why?
|
| Reminder Systems | 2 | 2020 | 74 | 0.300 |
Why?
|
| Sex Factors | 12 | 2019 | 976 | 0.300 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 660 | 0.300 |
Why?
|
| Hepatitis | 3 | 2023 | 56 | 0.300 |
Why?
|
| Hydrocortisone | 5 | 2016 | 193 | 0.290 |
Why?
|
| Stroke Volume | 4 | 2025 | 331 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 477 | 0.290 |
Why?
|
| Protective Devices | 1 | 2008 | 13 | 0.290 |
Why?
|
| Nursing Homes | 3 | 2010 | 671 | 0.290 |
Why?
|
| Smoking Cessation | 3 | 2020 | 551 | 0.280 |
Why?
|
| Referral and Consultation | 3 | 2020 | 422 | 0.280 |
Why?
|
| Stress, Psychological | 4 | 2019 | 469 | 0.280 |
Why?
|
| Cholesterol, HDL | 10 | 2010 | 73 | 0.280 |
Why?
|
| Reference Values | 5 | 2017 | 337 | 0.280 |
Why?
|
| Infant, Premature | 9 | 2008 | 183 | 0.280 |
Why?
|
| Frailty | 2 | 2019 | 130 | 0.270 |
Why?
|
| Double-Blind Method | 12 | 2024 | 739 | 0.270 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 5422 | 0.270 |
Why?
|
| Life Style | 3 | 2024 | 311 | 0.270 |
Why?
|
| Creatinine | 2 | 2024 | 135 | 0.260 |
Why?
|
| Vaccination | 2 | 2020 | 358 | 0.260 |
Why?
|
| Weight Loss | 2 | 2014 | 272 | 0.250 |
Why?
|
| Angina Pectoris | 2 | 2024 | 38 | 0.250 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 2450 | 0.250 |
Why?
|
| Complement System Proteins | 2 | 2024 | 115 | 0.250 |
Why?
|
| Fishes | 3 | 2000 | 20 | 0.250 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2017 | 30 | 0.250 |
Why?
|
| Radiologists | 2 | 2017 | 88 | 0.250 |
Why?
|
| Stress, Physiological | 3 | 2004 | 193 | 0.250 |
Why?
|
| Diet Records | 9 | 2010 | 34 | 0.240 |
Why?
|
| Alcoholism | 4 | 2024 | 319 | 0.240 |
Why?
|
| Analgesia | 2 | 2023 | 31 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2017 | 93 | 0.240 |
Why?
|
| Child of Impaired Parents | 1 | 2025 | 23 | 0.240 |
Why?
|
| Body Weights and Measures | 3 | 2021 | 33 | 0.240 |
Why?
|
| Pediatric Obesity | 3 | 2016 | 107 | 0.240 |
Why?
|
| Age Distribution | 4 | 2015 | 258 | 0.230 |
Why?
|
| Nutritive Value | 4 | 2009 | 30 | 0.230 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2025 | 22 | 0.230 |
Why?
|
| Coronary Sinus | 1 | 2024 | 5 | 0.230 |
Why?
|
| Antipsychotic Agents | 3 | 2013 | 302 | 0.230 |
Why?
|
| Antisickling Agents | 3 | 2009 | 5 | 0.230 |
Why?
|
| Hydroxyurea | 3 | 2009 | 19 | 0.230 |
Why?
|
| Constriction, Pathologic | 1 | 2025 | 121 | 0.230 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 23 | 0.230 |
Why?
|
| Pain, Postoperative | 2 | 2023 | 161 | 0.220 |
Why?
|
| Wharton Jelly | 2 | 2021 | 3 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2024 | 62 | 0.220 |
Why?
|
| Bupivacaine | 2 | 2023 | 35 | 0.220 |
Why?
|
| Amino Acids, Aromatic | 1 | 2023 | 7 | 0.220 |
Why?
|
| Pilot Projects | 4 | 2023 | 991 | 0.220 |
Why?
|
| Administration, Oral | 3 | 2019 | 368 | 0.210 |
Why?
|
| Interleukin-13 | 1 | 2023 | 37 | 0.210 |
Why?
|
| Regression Analysis | 13 | 2009 | 497 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 2 | 2021 | 98 | 0.210 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2009 | 168 | 0.210 |
Why?
|
| Emergency Medicine | 2 | 2017 | 188 | 0.210 |
Why?
|
| Laparoscopy | 2 | 2019 | 472 | 0.210 |
Why?
|
| Parturition | 2 | 2021 | 55 | 0.210 |
Why?
|
| Congenital Hypothyroidism | 1 | 2023 | 13 | 0.210 |
Why?
|
| Prevalence | 10 | 2019 | 1365 | 0.210 |
Why?
|
| Nutrition Policy | 4 | 2008 | 39 | 0.210 |
Why?
|
| Dietary Carbohydrates | 1 | 2003 | 61 | 0.210 |
Why?
|
| Thyroid Diseases | 1 | 2023 | 26 | 0.200 |
Why?
|
| Triglycerides | 10 | 2017 | 244 | 0.200 |
Why?
|
| Random Allocation | 2 | 2023 | 198 | 0.200 |
Why?
|
| Vasospasm, Intracranial | 2 | 2014 | 30 | 0.200 |
Why?
|
| Chronic Disease | 2 | 2025 | 751 | 0.200 |
Why?
|
| Hypothyroidism | 1 | 2023 | 42 | 0.200 |
Why?
|
| Weight Gain | 3 | 2015 | 170 | 0.200 |
Why?
|
| Administration, Intravenous | 2 | 2021 | 66 | 0.200 |
Why?
|
| Staphylococcal Infections | 2 | 2022 | 130 | 0.200 |
Why?
|
| Self Concept | 4 | 2016 | 111 | 0.200 |
Why?
|
| Probiotics | 1 | 2023 | 46 | 0.200 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 1141 | 0.200 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 281 | 0.200 |
Why?
|
| Pentoxifylline | 1 | 2022 | 8 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 3 | 2018 | 66 | 0.190 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 371 | 0.190 |
Why?
|
| Down Syndrome | 1 | 2023 | 47 | 0.190 |
Why?
|
| Pharmacists | 2 | 2020 | 124 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2017 | 225 | 0.190 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2023 | 87 | 0.190 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 11 | 0.190 |
Why?
|
| Proteomics | 1 | 2024 | 284 | 0.190 |
Why?
|
| Antimanic Agents | 1 | 2002 | 31 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 4 | 2007 | 47 | 0.190 |
Why?
|
| Text Messaging | 2 | 2020 | 85 | 0.190 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 143 | 0.190 |
Why?
|
| Atrial Function, Left | 2 | 2020 | 33 | 0.190 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2014 | 108 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 7 | 2024 | 117 | 0.190 |
Why?
|
| Insulin Infusion Systems | 1 | 2021 | 10 | 0.190 |
Why?
|
| Equipment and Supplies | 2 | 2012 | 19 | 0.190 |
Why?
|
| Mobile Applications | 2 | 2024 | 136 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1082 | 0.180 |
Why?
|
| Goats | 1 | 2021 | 11 | 0.180 |
Why?
|
| Kidney | 1 | 2024 | 444 | 0.180 |
Why?
|
| Infant | 8 | 2023 | 1626 | 0.180 |
Why?
|
| Tay-Sachs Disease | 1 | 2022 | 45 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 49 | 0.180 |
Why?
|
| Orthotic Devices | 1 | 2021 | 10 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 50 | 0.180 |
Why?
|
| Plagiocephaly | 1 | 2021 | 6 | 0.180 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 378 | 0.180 |
Why?
|
| Poloxamer | 1 | 2021 | 13 | 0.180 |
Why?
|
| Head Protective Devices | 1 | 2021 | 19 | 0.180 |
Why?
|
| Community-Acquired Infections | 1 | 2022 | 94 | 0.180 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 42 | 0.180 |
Why?
|
| Bacteremia | 1 | 2022 | 94 | 0.180 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 68 | 0.180 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 216 | 0.180 |
Why?
|
| Patient Transfer | 2 | 2020 | 93 | 0.180 |
Why?
|
| Gluconeogenesis | 1 | 2020 | 15 | 0.180 |
Why?
|
| Interviews as Topic | 2 | 2021 | 506 | 0.170 |
Why?
|
| Dietary Supplements | 3 | 2020 | 233 | 0.170 |
Why?
|
| Head | 1 | 2021 | 55 | 0.170 |
Why?
|
| Health Status | 4 | 2014 | 433 | 0.170 |
Why?
|
| House Calls | 1 | 2020 | 23 | 0.170 |
Why?
|
| Influenza, Human | 2 | 2020 | 207 | 0.170 |
Why?
|
| Osteoporosis | 2 | 2012 | 108 | 0.170 |
Why?
|
| Caffeine | 2 | 2006 | 49 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2021 | 170 | 0.170 |
Why?
|
| Age of Onset | 1 | 2020 | 175 | 0.170 |
Why?
|
| Internship and Residency | 3 | 2021 | 793 | 0.170 |
Why?
|
| Breeding | 2 | 2018 | 26 | 0.170 |
Why?
|
| Drug Therapy, Combination | 7 | 2013 | 464 | 0.170 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 160 | 0.170 |
Why?
|
| Logistic Models | 8 | 2025 | 1275 | 0.170 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2020 | 33 | 0.170 |
Why?
|
| Overweight | 2 | 2016 | 250 | 0.170 |
Why?
|
| Thrombocytosis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Health Behavior | 4 | 2024 | 466 | 0.170 |
Why?
|
| Gastropexy | 1 | 2019 | 1 | 0.170 |
Why?
|
| Placebos | 6 | 2021 | 71 | 0.170 |
Why?
|
| Hypertension | 4 | 2015 | 590 | 0.170 |
Why?
|
| Stomach Volvulus | 1 | 2019 | 3 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2021 | 152 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 350 | 0.160 |
Why?
|
| Thrombophilia | 1 | 2020 | 14 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 123 | 0.160 |
Why?
|
| Adipose Tissue | 7 | 2002 | 296 | 0.160 |
Why?
|
| Respiration, Artificial | 6 | 2007 | 295 | 0.160 |
Why?
|
| Safety Management | 2 | 2014 | 137 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 80 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 666 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 731 | 0.160 |
Why?
|
| Eating | 4 | 2012 | 138 | 0.160 |
Why?
|
| Deep Sedation | 1 | 2019 | 4 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 233 | 0.160 |
Why?
|
| Recurrence | 5 | 2015 | 638 | 0.160 |
Why?
|
| Mental Health | 2 | 2019 | 364 | 0.160 |
Why?
|
| Bipolar Disorder | 1 | 2002 | 246 | 0.160 |
Why?
|
| Forelimb | 1 | 2019 | 9 | 0.160 |
Why?
|
| Synovial Fluid | 1 | 2019 | 29 | 0.160 |
Why?
|
| Molecular Typing | 1 | 2019 | 9 | 0.160 |
Why?
|
| Sexual Maturation | 5 | 2003 | 51 | 0.160 |
Why?
|
| Acute-Phase Proteins | 1 | 2019 | 34 | 0.160 |
Why?
|
| Sample Size | 3 | 2019 | 65 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 72 | 0.160 |
Why?
|
| Perfusion | 1 | 2019 | 73 | 0.160 |
Why?
|
| Coronary Occlusion | 2 | 2009 | 6 | 0.150 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 57 | 0.150 |
Why?
|
| Health Expenditures | 2 | 2024 | 122 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2016 | 294 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 67 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 220 | 0.150 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 775 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 119 | 0.150 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2019 | 28 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 79 | 0.150 |
Why?
|
| Stroke | 5 | 2019 | 1190 | 0.150 |
Why?
|
| Estradiol | 4 | 2010 | 257 | 0.150 |
Why?
|
| Testosterone | 4 | 2009 | 119 | 0.150 |
Why?
|
| Protective Clothing | 2 | 2010 | 29 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 114 | 0.150 |
Why?
|
| Cerebral Infarction | 2 | 2010 | 83 | 0.150 |
Why?
|
| Micronutrients | 2 | 2009 | 21 | 0.150 |
Why?
|
| Cues | 1 | 2019 | 76 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 57 | 0.150 |
Why?
|
| Adenosine | 1 | 2019 | 78 | 0.150 |
Why?
|
| Massachusetts | 6 | 2019 | 2061 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 45 | 0.150 |
Why?
|
| Cattle Diseases | 1 | 2018 | 10 | 0.150 |
Why?
|
| Proportional Hazards Models | 5 | 2025 | 729 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 173 | 0.150 |
Why?
|
| Phlebotomy | 1 | 2018 | 7 | 0.150 |
Why?
|
| Comorbidity | 4 | 2019 | 1119 | 0.150 |
Why?
|
| Hepatitis C | 2 | 2011 | 151 | 0.150 |
Why?
|
| Mindfulness | 1 | 2019 | 69 | 0.140 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 71 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 172 | 0.140 |
Why?
|
| Thromboxane A2 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 348 | 0.140 |
Why?
|
| Data Collection | 2 | 2022 | 384 | 0.140 |
Why?
|
| Ataxia | 1 | 2017 | 23 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 106 | 0.140 |
Why?
|
| Health Policy | 1 | 2019 | 190 | 0.140 |
Why?
|
| Medical Laboratory Personnel | 1 | 2017 | 9 | 0.140 |
Why?
|
| Deficiency Diseases | 1 | 2017 | 13 | 0.140 |
Why?
|
| Brain | 3 | 2022 | 1554 | 0.140 |
Why?
|
| Iodine | 1 | 2017 | 19 | 0.140 |
Why?
|
| Metabolic Syndrome | 2 | 2011 | 143 | 0.140 |
Why?
|
| Heart Atria | 1 | 2018 | 138 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 355 | 0.140 |
Why?
|
| Depressive Disorder, Major | 2 | 2013 | 254 | 0.140 |
Why?
|
| Touch | 1 | 2017 | 27 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2017 | 82 | 0.140 |
Why?
|
| Social Support | 2 | 2019 | 370 | 0.130 |
Why?
|
| Myocardial Infarction | 5 | 2017 | 911 | 0.130 |
Why?
|
| Simvastatin | 1 | 2017 | 27 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1160 | 0.130 |
Why?
|
| Diet Surveys | 3 | 2007 | 44 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2016 | 14 | 0.130 |
Why?
|
| Carbonated Beverages | 2 | 2007 | 21 | 0.130 |
Why?
|
| Recombinant Proteins | 7 | 2013 | 700 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 98 | 0.130 |
Why?
|
| Postpartum Period | 2 | 2017 | 195 | 0.130 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2017 | 37 | 0.130 |
Why?
|
| Fertility | 1 | 1996 | 80 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 716 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2020 | 518 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2010 | 306 | 0.130 |
Why?
|
| Georgia | 3 | 2022 | 87 | 0.130 |
Why?
|
| Gait | 1 | 2017 | 119 | 0.130 |
Why?
|
| Diphtheria | 1 | 2016 | 6 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 19 | 0.130 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2016 | 17 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2016 | 49 | 0.130 |
Why?
|
| Diphtheria Toxin | 1 | 2016 | 7 | 0.130 |
Why?
|
| Diphtheria Antitoxin | 1 | 2016 | 5 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 195 | 0.130 |
Why?
|
| Autoantibodies | 2 | 2017 | 182 | 0.130 |
Why?
|
| Lactation | 4 | 2020 | 69 | 0.130 |
Why?
|
| Communication Barriers | 1 | 2016 | 62 | 0.130 |
Why?
|
| Fear | 1 | 2016 | 70 | 0.130 |
Why?
|
| Bulimia Nervosa | 2 | 2006 | 10 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 433 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 54 | 0.130 |
Why?
|
| Hotlines | 1 | 2016 | 21 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2016 | 138 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2019 | 277 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 669 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2016 | 39 | 0.120 |
Why?
|
| Pregnancy Outcome | 2 | 2009 | 193 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 75 | 0.120 |
Why?
|
| Gestational Age | 5 | 2023 | 189 | 0.120 |
Why?
|
| School Health Services | 1 | 2016 | 64 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 57 | 0.120 |
Why?
|
| Educational Status | 4 | 2023 | 274 | 0.120 |
Why?
|
| Progesterone | 3 | 2016 | 163 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 297 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 24 | 0.120 |
Why?
|
| Jejunal Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cecal Neoplasms | 1 | 2015 | 2 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 2015 | 5 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2015 | 242 | 0.120 |
Why?
|
| Fibrosarcoma | 1 | 2015 | 13 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 190 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2015 | 9 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 331 | 0.120 |
Why?
|
| Hyperaldosteronism | 1 | 2015 | 5 | 0.120 |
Why?
|
| Vegetables | 2 | 2006 | 67 | 0.120 |
Why?
|
| Hypokalemia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Leiomyoma | 1 | 2015 | 17 | 0.120 |
Why?
|
| Learning Curve | 1 | 2015 | 35 | 0.120 |
Why?
|
| Health Promotion | 3 | 2016 | 493 | 0.120 |
Why?
|
| Fruit | 2 | 2006 | 107 | 0.120 |
Why?
|
| Sarcoma | 1 | 2015 | 36 | 0.120 |
Why?
|
| Coxsackievirus Infections | 1 | 2014 | 12 | 0.120 |
Why?
|
| Dantrolene | 1 | 2014 | 8 | 0.120 |
Why?
|
| Muscle Relaxants, Central | 1 | 2014 | 12 | 0.120 |
Why?
|
| Rhode Island | 1 | 2015 | 100 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2006 | 31 | 0.110 |
Why?
|
| Bronchitis, Chronic | 1 | 2014 | 17 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 217 | 0.110 |
Why?
|
| Body Fat Distribution | 2 | 2012 | 13 | 0.110 |
Why?
|
| Liver Cirrhosis | 2 | 2013 | 171 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2010 | 17 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 641 | 0.110 |
Why?
|
| Adenoma | 1 | 2015 | 68 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2019 | 981 | 0.110 |
Why?
|
| Pressure Ulcer | 1 | 2014 | 35 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 755 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2019 | 706 | 0.110 |
Why?
|
| Pulse | 1 | 1994 | 16 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 78 | 0.110 |
Why?
|
| Bronchi | 1 | 2014 | 77 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2013 | 141 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 28 | 0.110 |
Why?
|
| Blood Transfusion | 2 | 2018 | 161 | 0.110 |
Why?
|
| Vitiligo | 1 | 2017 | 126 | 0.110 |
Why?
|
| Zinc | 3 | 2024 | 92 | 0.110 |
Why?
|
| Fingers | 1 | 1994 | 46 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2014 | 25 | 0.110 |
Why?
|
| Yttrium Radioisotopes | 1 | 2013 | 7 | 0.110 |
Why?
|
| Maternal Health Services | 1 | 2015 | 66 | 0.110 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2014 | 176 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 934 | 0.110 |
Why?
|
| Self Report | 2 | 2014 | 371 | 0.110 |
Why?
|
| Pain Measurement | 4 | 2009 | 343 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 104 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 680 | 0.110 |
Why?
|
| Crime | 1 | 2014 | 53 | 0.110 |
Why?
|
| Criminal Law | 1 | 2014 | 72 | 0.110 |
Why?
|
| Morpholinos | 1 | 2013 | 52 | 0.110 |
Why?
|
| Sertraline | 1 | 2013 | 58 | 0.110 |
Why?
|
| Disease Management | 1 | 2015 | 234 | 0.100 |
Why?
|
| Growth | 3 | 2002 | 22 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 309 | 0.100 |
Why?
|
| Perception | 1 | 2014 | 173 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 419 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2024 | 27 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 39 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2019 | 769 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2013 | 100 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 315 | 0.100 |
Why?
|
| Birth Weight | 3 | 2023 | 85 | 0.100 |
Why?
|
| Islets of Langerhans | 1 | 2014 | 279 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 892 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 57 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2013 | 54 | 0.100 |
Why?
|
| Health Services Research | 1 | 2014 | 270 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2015 | 479 | 0.100 |
Why?
|
| Patient Selection | 2 | 2012 | 483 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2015 | 854 | 0.100 |
Why?
|
| Hospitalization | 1 | 2020 | 1347 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2012 | 29 | 0.100 |
Why?
|
| Depression | 3 | 2019 | 884 | 0.100 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 76 | 0.100 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 56 | 0.100 |
Why?
|
| Medical Errors | 1 | 2014 | 195 | 0.100 |
Why?
|
| Nutritional Requirements | 2 | 2008 | 20 | 0.090 |
Why?
|
| Skinfold Thickness | 9 | 2005 | 16 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2016 | 1292 | 0.090 |
Why?
|
| Dementia | 1 | 2015 | 258 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 870 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2012 | 96 | 0.090 |
Why?
|
| Anesthetics, Local | 2 | 2023 | 71 | 0.090 |
Why?
|
| Behavior | 1 | 2011 | 36 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 157 | 0.090 |
Why?
|
| Videodisc Recording | 1 | 2011 | 8 | 0.090 |
Why?
|
| Perches | 1 | 2010 | 2 | 0.090 |
Why?
|
| Biogenic Monoamines | 1 | 2010 | 5 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 203 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 149 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 231 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 283 | 0.090 |
Why?
|
| Cluster Analysis | 2 | 2023 | 258 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 453 | 0.090 |
Why?
|
| Matched-Pair Analysis | 2 | 2008 | 10 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2010 | 42 | 0.090 |
Why?
|
| Trace Elements | 3 | 2007 | 20 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2011 | 148 | 0.090 |
Why?
|
| Insulin Resistance | 4 | 2011 | 410 | 0.090 |
Why?
|
| Waist Circumference | 1 | 2010 | 45 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 138 | 0.090 |
Why?
|
| Nicotine | 1 | 2011 | 117 | 0.080 |
Why?
|
| Health Literacy | 1 | 2011 | 83 | 0.080 |
Why?
|
| United Kingdom | 3 | 2017 | 80 | 0.080 |
Why?
|
| Sickness Impact Profile | 2 | 2009 | 46 | 0.080 |
Why?
|
| Hypothalamus | 1 | 2010 | 132 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 191 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2016 | 685 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 554 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 196 | 0.080 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 20 | 0.080 |
Why?
|
| Incidence | 4 | 2018 | 1373 | 0.080 |
Why?
|
| Family Relations | 1 | 2009 | 23 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1351 | 0.080 |
Why?
|
| Metals | 1 | 2009 | 65 | 0.080 |
Why?
|
| Body Constitution | 3 | 1998 | 16 | 0.080 |
Why?
|
| Ethanol | 2 | 2023 | 321 | 0.080 |
Why?
|
| Anesthesia, Obstetrical | 1 | 1988 | 24 | 0.080 |
Why?
|
| Food Analysis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Circadian Rhythm | 2 | 2004 | 381 | 0.080 |
Why?
|
| Saliva | 2 | 2021 | 103 | 0.080 |
Why?
|
| Emotions | 1 | 2011 | 223 | 0.080 |
Why?
|
| Peripartum Period | 2 | 2020 | 21 | 0.080 |
Why?
|
| Anesthesia, Spinal | 1 | 1988 | 30 | 0.070 |
Why?
|
| Vitamins | 2 | 2007 | 81 | 0.070 |
Why?
|
| Child Behavior | 1 | 2009 | 64 | 0.070 |
Why?
|
| Intensive Care, Neonatal | 2 | 2007 | 10 | 0.070 |
Why?
|
| Food Preferences | 2 | 2006 | 51 | 0.070 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 62 | 0.070 |
Why?
|
| Juvenile Delinquency | 1 | 2009 | 56 | 0.070 |
Why?
|
| Labor, Obstetric | 1 | 1988 | 38 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2009 | 200 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 78 | 0.070 |
Why?
|
| beta-Thalassemia | 1 | 2008 | 13 | 0.070 |
Why?
|
| Nutrition Surveys | 3 | 2017 | 142 | 0.070 |
Why?
|
| Prosthesis Design | 2 | 2024 | 223 | 0.070 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 83 | 0.070 |
Why?
|
| Cholesterol, Dietary | 3 | 2003 | 29 | 0.070 |
Why?
|
| Radiology Information Systems | 1 | 2008 | 34 | 0.070 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2007 | 18 | 0.070 |
Why?
|
| Education, Medical, Graduate | 4 | 2021 | 344 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 137 | 0.070 |
Why?
|
| ROC Curve | 2 | 2019 | 280 | 0.070 |
Why?
|
| Social Environment | 1 | 2008 | 93 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 28 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 2007 | 54 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 103 | 0.070 |
Why?
|
| Mammography | 1 | 2010 | 280 | 0.070 |
Why?
|
| Cause of Death | 2 | 2019 | 222 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 644 | 0.070 |
Why?
|
| Adolescent Behavior | 2 | 2006 | 194 | 0.070 |
Why?
|
| Panic Disorder | 2 | 2005 | 32 | 0.070 |
Why?
|
| Remission Induction | 2 | 2017 | 147 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 46 | 0.070 |
Why?
|
| Thyroxine | 2 | 2023 | 53 | 0.070 |
Why?
|
| Mental Recall | 1 | 2007 | 91 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2023 | 78 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 252 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2007 | 80 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2006 | 57 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 10 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2006 | 16 | 0.060 |
Why?
|
| Drinking Behavior | 1 | 2006 | 9 | 0.060 |
Why?
|
| Healthy People Programs | 1 | 2006 | 11 | 0.060 |
Why?
|
| Pediatrics | 3 | 2016 | 251 | 0.060 |
Why?
|
| Bulimia | 1 | 2006 | 17 | 0.060 |
Why?
|
| Anthropometry | 4 | 2015 | 87 | 0.060 |
Why?
|
| Family | 1 | 2008 | 240 | 0.060 |
Why?
|
| Caregivers | 1 | 2009 | 268 | 0.060 |
Why?
|
| Demography | 4 | 2015 | 174 | 0.060 |
Why?
|
| Salmon | 1 | 1985 | 8 | 0.060 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1985 | 19 | 0.060 |
Why?
|
| Postmenopause | 2 | 2005 | 237 | 0.060 |
Why?
|
| Diet, Atherogenic | 1 | 2005 | 7 | 0.060 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2005 | 12 | 0.060 |
Why?
|
| Blood Specimen Collection | 1 | 2005 | 20 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 249 | 0.060 |
Why?
|
| Dairy Products | 1 | 2005 | 15 | 0.060 |
Why?
|
| Inflammation | 2 | 2023 | 1142 | 0.060 |
Why?
|
| Stents | 1 | 2009 | 487 | 0.060 |
Why?
|
| Meat | 1 | 2005 | 34 | 0.060 |
Why?
|
| Warfarin | 1 | 2006 | 110 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2005 | 144 | 0.060 |
Why?
|
| Somatoform Disorders | 1 | 2004 | 13 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 864 | 0.060 |
Why?
|
| Hypotension | 1 | 2005 | 50 | 0.060 |
Why?
|
| Mice | 4 | 2023 | 10826 | 0.060 |
Why?
|
| Body Image | 1 | 2004 | 31 | 0.060 |
Why?
|
| Operative Time | 1 | 2024 | 91 | 0.060 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 43 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 93 | 0.060 |
Why?
|
| Hierarchy, Social | 1 | 2004 | 1 | 0.060 |
Why?
|
| Dominance-Subordination | 1 | 2004 | 2 | 0.060 |
Why?
|
| Oncorhynchus mykiss | 1 | 2004 | 2 | 0.060 |
Why?
|
| Mental Disorders | 2 | 2014 | 756 | 0.060 |
Why?
|
| Life Change Events | 1 | 2004 | 66 | 0.060 |
Why?
|
| Exome | 1 | 2024 | 77 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 667 | 0.060 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 9 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Motor Activity | 1 | 2006 | 345 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 16 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 19 | 0.050 |
Why?
|
| Prednisone | 1 | 2024 | 86 | 0.050 |
Why?
|
| Tryptophan | 1 | 2023 | 58 | 0.050 |
Why?
|
| Systole | 4 | 1998 | 109 | 0.050 |
Why?
|
| Asthma | 1 | 2008 | 433 | 0.050 |
Why?
|
| Aggression | 1 | 2004 | 64 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2023 | 14 | 0.050 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 174 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 94 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2023 | 102 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2003 | 41 | 0.050 |
Why?
|
| Thyrotropin | 1 | 2023 | 34 | 0.050 |
Why?
|
| Proteome | 1 | 2024 | 149 | 0.050 |
Why?
|
| Glucose Intolerance | 1 | 2004 | 90 | 0.050 |
Why?
|
| Risk | 3 | 2017 | 377 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 67 | 0.050 |
Why?
|
| Psychometrics | 3 | 2016 | 377 | 0.050 |
Why?
|
| Hospitals | 2 | 2017 | 393 | 0.050 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2023 | 67 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2019 | 580 | 0.050 |
Why?
|
| Caspase 1 | 1 | 2023 | 111 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2005 | 285 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2022 | 20 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 34 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2025 | 314 | 0.050 |
Why?
|
| Leukocidins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exotoxins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Lipoproteins | 2 | 2006 | 83 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 364 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 320 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 516 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 416 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 61 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 496 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 80 | 0.050 |
Why?
|
| Self Care | 2 | 2015 | 212 | 0.050 |
Why?
|
| Colostrum | 1 | 2021 | 6 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 299 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2023 | 263 | 0.050 |
Why?
|
| Health Education | 1 | 2003 | 189 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2181 | 0.050 |
Why?
|
| Viral Load | 1 | 2022 | 231 | 0.050 |
Why?
|
| Reference Standards | 1 | 2021 | 73 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 108 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 76 | 0.040 |
Why?
|
| Prenatal Care | 2 | 2020 | 173 | 0.040 |
Why?
|
| Complement Factor D | 1 | 2020 | 4 | 0.040 |
Why?
|
| Complement C5 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Complement C4 | 1 | 2020 | 11 | 0.040 |
Why?
|
| Complement C2 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Complement Factor B | 1 | 2020 | 11 | 0.040 |
Why?
|
| Rumen | 1 | 2020 | 2 | 0.040 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2020 | 15 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 258 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 135 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 208 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2017 | 307 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 177 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 173 | 0.040 |
Why?
|
| Complement C3 | 1 | 2020 | 59 | 0.040 |
Why?
|
| Stifle | 1 | 2020 | 2 | 0.040 |
Why?
|
| Colorado | 1 | 2020 | 21 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2021 | 81 | 0.040 |
Why?
|
| Osteotomy | 1 | 2020 | 17 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 127 | 0.040 |
Why?
|
| Social Class | 2 | 2002 | 133 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 2000 | 110 | 0.040 |
Why?
|
| Spouses | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chlorides | 1 | 2000 | 31 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 3 | 0.040 |
Why?
|
| Keratin-18 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2021 | 118 | 0.040 |
Why?
|
| Seroma | 1 | 2019 | 8 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2017 | 378 | 0.040 |
Why?
|
| Restraint, Physical | 1 | 2000 | 40 | 0.040 |
Why?
|
| New Jersey | 1 | 2019 | 26 | 0.040 |
Why?
|
| Neurokinin A | 1 | 1999 | 4 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 42 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2000 | 75 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 57 | 0.040 |
Why?
|
| Substance P | 1 | 1999 | 38 | 0.040 |
Why?
|
| Surgical Wound | 1 | 2019 | 10 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 3027 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 1999 | 76 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 120 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 119 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 284 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 53 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 39 | 0.040 |
Why?
|
| Urban Population | 2 | 2011 | 190 | 0.040 |
Why?
|
| Functional Neuroimaging | 1 | 2019 | 14 | 0.040 |
Why?
|
| Midazolam | 1 | 1999 | 12 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 32 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1992 | 98 | 0.040 |
Why?
|
| Anesthetics, Intravenous | 1 | 1999 | 26 | 0.040 |
Why?
|
| Galanin | 1 | 1999 | 4 | 0.040 |
Why?
|
| Tachykinins | 1 | 1999 | 7 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2019 | 64 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 334 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2019 | 85 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 98 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2019 | 109 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 96 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 115 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 92 | 0.040 |
Why?
|
| Animal Feed | 2 | 1998 | 16 | 0.040 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2019 | 57 | 0.040 |
Why?
|
| Biometry | 1 | 1998 | 12 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2021 | 493 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2021 | 938 | 0.040 |
Why?
|
| Canada | 2 | 2009 | 154 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 393 | 0.040 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2017 | 2 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 455 | 0.040 |
Why?
|
| Models, Biological | 2 | 2017 | 1181 | 0.040 |
Why?
|
| Urinalysis | 1 | 2017 | 38 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 942 | 0.040 |
Why?
|
| Vitamin D | 2 | 2010 | 139 | 0.030 |
Why?
|
| Anion Transport Proteins | 1 | 2017 | 3 | 0.030 |
Why?
|
| Time | 1 | 2017 | 30 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 33 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 385 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 118 | 0.030 |
Why?
|
| Sex Ratio | 1 | 1997 | 8 | 0.030 |
Why?
|
| Carrier State | 1 | 2017 | 18 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 51 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 838 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 317 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2017 | 11 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2017 | 49 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 1997 | 14 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 478 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2017 | 58 | 0.030 |
Why?
|
| Diastole | 4 | 1998 | 92 | 0.030 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2007 | 6 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 310 | 0.030 |
Why?
|
| School Nursing | 1 | 2016 | 26 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1996 | 56 | 0.030 |
Why?
|
| 20-alpha-Dihydroprogesterone | 1 | 2016 | 7 | 0.030 |
Why?
|
| Desoxycorticosterone | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pregnanolone | 1 | 2016 | 14 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2016 | 19 | 0.030 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1996 | 36 | 0.030 |
Why?
|
| Paralysis | 1 | 2016 | 17 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2016 | 84 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 409 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 25 | 0.030 |
Why?
|
| Anxiety | 1 | 2019 | 423 | 0.030 |
Why?
|
| Horses | 1 | 2016 | 55 | 0.030 |
Why?
|
| Food | 2 | 2008 | 76 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 71 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 506 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2108 | 0.030 |
Why?
|
| Procollagen | 1 | 2015 | 10 | 0.030 |
Why?
|
| Child Welfare | 1 | 1996 | 52 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2015 | 41 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 85 | 0.030 |
Why?
|
| Dependovirus | 1 | 2022 | 695 | 0.030 |
Why?
|
| Femur | 1 | 2015 | 53 | 0.030 |
Why?
|
| Heart Rate | 2 | 2008 | 321 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2017 | 257 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 120 | 0.030 |
Why?
|
| Psychology | 1 | 2015 | 44 | 0.030 |
Why?
|
| Spine | 1 | 2015 | 48 | 0.030 |
Why?
|
| Androstenedione | 2 | 2006 | 8 | 0.030 |
Why?
|
| General Surgery | 2 | 1974 | 207 | 0.030 |
Why?
|
| Leukomalacia, Periventricular | 2 | 2005 | 10 | 0.030 |
Why?
|
| Bronchography | 1 | 2014 | 3 | 0.030 |
Why?
|
| Population Density | 1 | 1974 | 14 | 0.030 |
Why?
|
| Patient Isolation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2022 | 772 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2014 | 17 | 0.030 |
Why?
|
| Mothers | 2 | 1996 | 275 | 0.030 |
Why?
|
| Brassica | 1 | 1994 | 7 | 0.030 |
Why?
|
| Menarche | 2 | 2006 | 37 | 0.030 |
Why?
|
| Arm | 1 | 1994 | 45 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2157 | 0.030 |
Why?
|
| Blood Volume | 1 | 1994 | 42 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 102 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 467 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 845 | 0.030 |
Why?
|
| Sheep | 1 | 1994 | 179 | 0.030 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 38 | 0.030 |
Why?
|
| Technetium | 1 | 2013 | 68 | 0.030 |
Why?
|
| Injections | 1 | 2013 | 81 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 486 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 216 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 127 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2013 | 14 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 411 | 0.030 |
Why?
|
| Safety | 2 | 2008 | 145 | 0.030 |
Why?
|
| Women's Health | 1 | 1996 | 369 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2013 | 120 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1994 | 245 | 0.030 |
Why?
|
| Radio | 1 | 2012 | 2 | 0.030 |
Why?
|
| Digestion | 1 | 1994 | 144 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 137 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 35 | 0.030 |
Why?
|
| Water | 1 | 1994 | 308 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1184 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1992 | 39 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2013 | 187 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 199 | 0.020 |
Why?
|
| Homeostasis | 2 | 2005 | 368 | 0.020 |
Why?
|
| Smoking | 3 | 2008 | 864 | 0.020 |
Why?
|
| Ferritins | 2 | 2003 | 31 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 183 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 431 | 0.020 |
Why?
|
| Peptides | 1 | 2015 | 577 | 0.020 |
Why?
|
| Apolipoproteins B | 2 | 2003 | 19 | 0.020 |
Why?
|
| Coronary Disease | 2 | 1998 | 246 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 589 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 1335 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 47 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 1508 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 521 | 0.020 |
Why?
|
| Sampling Studies | 2 | 2003 | 68 | 0.020 |
Why?
|
| Culture | 1 | 2011 | 78 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 67 | 0.020 |
Why?
|
| Income | 3 | 2002 | 169 | 0.020 |
Why?
|
| Phenotype | 2 | 2008 | 1198 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 154 | 0.020 |
Why?
|
| Climate | 1 | 2009 | 4 | 0.020 |
Why?
|
| Atmospheric Pressure | 1 | 2009 | 3 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 60 | 0.020 |
Why?
|
| Wind | 1 | 2009 | 4 | 0.020 |
Why?
|
| Postural Balance | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1460 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2009 | 50 | 0.020 |
Why?
|
| Fetus | 1 | 2009 | 99 | 0.020 |
Why?
|
| Legal Guardians | 1 | 2009 | 7 | 0.020 |
Why?
|
| Adolescent Development | 1 | 2009 | 16 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 276 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 133 | 0.020 |
Why?
|
| Estrus | 1 | 1988 | 26 | 0.020 |
Why?
|
| Obstetrical Forceps | 1 | 1988 | 2 | 0.020 |
Why?
|
| Butorphanol | 1 | 1988 | 4 | 0.020 |
Why?
|
| Apgar Score | 1 | 1988 | 11 | 0.020 |
Why?
|
| Anesthesia, Intravenous | 1 | 1988 | 14 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 447 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1999 | 231 | 0.020 |
Why?
|
| Adaptation, Psychological | 2 | 2004 | 265 | 0.020 |
Why?
|
| Suction | 1 | 2008 | 35 | 0.020 |
Why?
|
| Poverty | 1 | 2011 | 295 | 0.020 |
Why?
|
| France | 1 | 2008 | 14 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 309 | 0.020 |
Why?
|
| Siblings | 1 | 2008 | 44 | 0.020 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2007 | 15 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 157 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 211 | 0.020 |
Why?
|
| Vitamin A | 1 | 2007 | 28 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2008 | 162 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 56 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 269 | 0.020 |
Why?
|
| Magnesium | 1 | 2007 | 52 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 432 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 57 | 0.020 |
Why?
|
| Cisplatin | 1 | 1987 | 140 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 716 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2006 | 6 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 574 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 66 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2006 | 33 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 19 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 98 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 204 | 0.020 |
Why?
|
| Virginia | 1 | 2005 | 25 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 1595 | 0.020 |
Why?
|
| Dietary Sucrose | 1 | 2006 | 24 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 34 | 0.020 |
Why?
|
| Gills | 1 | 1985 | 6 | 0.020 |
Why?
|
| Fresh Water | 1 | 1985 | 12 | 0.020 |
Why?
|
| Seawater | 1 | 1985 | 11 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 1997 | 0.020 |
Why?
|
| Rest | 1 | 1985 | 45 | 0.020 |
Why?
|
| Twins | 1 | 2005 | 52 | 0.020 |
Why?
|
| Phobic Disorders | 1 | 2005 | 15 | 0.010 |
Why?
|
| Maternal Age | 1 | 2005 | 34 | 0.010 |
Why?
|
| Goals | 1 | 2006 | 91 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2005 | 31 | 0.010 |
Why?
|
| Respiration | 1 | 2005 | 89 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2004 | 28 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2004 | 33 | 0.010 |
Why?
|
| Software | 1 | 2008 | 384 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 69 | 0.010 |
Why?
|
| Hyperphagia | 1 | 2004 | 18 | 0.010 |
Why?
|
| Infant Mortality | 1 | 2004 | 20 | 0.010 |
Why?
|
| Individuality | 1 | 2004 | 22 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1985 | 608 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 179 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 2599 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 47 | 0.010 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 66 | 0.010 |
Why?
|
| Apolipoprotein A-II | 1 | 2003 | 1 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 28 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 2003 | 23 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 2003 | 18 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 671 | 0.010 |
Why?
|
| Estrone | 1 | 2003 | 13 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 2003 | 13 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2003 | 45 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 53 | 0.010 |
Why?
|
| Registries | 1 | 2005 | 877 | 0.010 |
Why?
|
| Electric Impedance | 1 | 2001 | 36 | 0.010 |
Why?
|
| Learning | 1 | 2003 | 178 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2000 | 20 | 0.010 |
Why?
|
| Hematocrit | 2 | 1994 | 33 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 397 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1003 | 0.010 |
Why?
|
| Child Development | 1 | 2001 | 83 | 0.010 |
Why?
|
| Trout | 1 | 1999 | 5 | 0.010 |
Why?
|
| Sequence Homology | 1 | 1999 | 20 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1999 | 188 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 709 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1999 | 63 | 0.010 |
Why?
|
| Dairying | 1 | 1998 | 2 | 0.010 |
Why?
|
| Social Desirability | 1 | 1997 | 6 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1999 | 305 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 1997 | 2 | 0.010 |
Why?
|
| Minerals | 1 | 1997 | 20 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 104 | 0.010 |
Why?
|
| Folic Acid | 1 | 1997 | 41 | 0.010 |
Why?
|
| Automatism | 1 | 1996 | 1 | 0.010 |
Why?
|
| Defense Mechanisms | 1 | 1996 | 6 | 0.010 |
Why?
|
| Personality Disorders | 1 | 1996 | 19 | 0.010 |
Why?
|
| Temperance | 1 | 1996 | 13 | 0.010 |
Why?
|
| Leisure Activities | 1 | 1996 | 26 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1997 | 149 | 0.010 |
Why?
|
| Television | 1 | 1996 | 21 | 0.010 |
Why?
|
| Health Surveys | 1 | 1997 | 313 | 0.010 |
Why?
|
| South Carolina | 1 | 1996 | 14 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 193 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 1996 | 37 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1996 | 93 | 0.010 |
Why?
|
| Ohio | 1 | 1994 | 24 | 0.010 |
Why?
|
| Maryland | 1 | 1994 | 35 | 0.010 |
Why?
|
| Schools | 1 | 1996 | 159 | 0.010 |
Why?
|
| Poaceae | 1 | 1994 | 4 | 0.010 |
Why?
|
| Sheep Diseases | 1 | 1994 | 4 | 0.010 |
Why?
|
| Drinking | 1 | 1994 | 14 | 0.010 |
Why?
|
| California | 1 | 1994 | 174 | 0.010 |
Why?
|
| Cellulose | 1 | 1994 | 43 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1994 | 81 | 0.010 |
Why?
|
| Feces | 1 | 1994 | 112 | 0.010 |
Why?
|
| Anemia | 1 | 1994 | 127 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1992 | 337 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1987 | 65 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1987 | 490 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1985 | 17 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1985 | 96 | 0.000 |
Why?
|
| Uric Acid | 1 | 1985 | 47 | 0.000 |
Why?
|
| Diuretics | 1 | 1985 | 63 | 0.000 |
Why?
|
| Foreign Medical Graduates | 1 | 1974 | 3 | 0.000 |
Why?
|
| Economics, Medical | 1 | 1974 | 3 | 0.000 |
Why?
|
| Legislation, Medical | 1 | 1974 | 4 | 0.000 |
Why?
|
| Professional Practice | 1 | 1974 | 24 | 0.000 |
Why?
|
| Certification | 1 | 1974 | 50 | 0.000 |
Why?
|
| Specialization | 1 | 1974 | 81 | 0.000 |
Why?
|
| Education, Medical | 1 | 1974 | 182 | 0.000 |
Why?
|